Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

This study is currently recruiting participants.

For detailed information about the trial please visit Clinicaltrials.gov

For enrollment please contact the Investigators at the clinical trial sites below.


Current Clinical Trial Locations

United States, Minneapolis, Minnesota

Virginia Piper Cancer Institute, part of Allina Health System

Minneapolis, Minnesota, United States, 55407

Contact: Stephanie Erickson

Telephone: 1-612-863-1752

Email: Stephanie.Erickson2@allina.com

Principal Investigator: Samith T Kochuparambil, MD   

 

United States, Chicago, Illinois

Rush University Cancer Center

Chicago, Illinois, United States, 60612

Contact: Pam Sroka, BS, MT (ASCP), BSN, RN, CCRC

Telephone: 1-312-942-5526    

Email: pamela_sroka@rush.edu 

Principal Investigator: Mary Jo Fidler, MD        

 

United States, Oklahoma City, Oklahoma

University of Oklahoma Stephenson Cancer Center

Oklahoma City, Oklahoma, United States, 73104

Contact: Dena Suthers  

Telephone: 405-271-8001 x48971

Email: dena-suthers@ouhsc.edu 

Principal Investigator: Nilesh Vasan, MD 

 

United States, Philadelphia, Pennsylvania

Thomas Jefferson University

Philadelphia, Pennsylvania, United States, 19107

Contact:

Dawn Poller

Telephone: 215-955-1964

Email: Dawn.Poller@jefferson.edu 

Principal Investigator: David Cognetti, MD 

 

United States, Houston Txas

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Contact: Heather Jamieson

Telephone: 713-792-6478

Email: hjamieso@mdanderson.org

Principal Investigator: Ann M Gillenwater, MD

 

United States, Denver, Colorado

Centura Health Research Center       

Denver, Colorado, United States, 80210

Contact: Sheryl Giambartolomei, RN

Telephone: 1-303-765-3536   

Email: sherylgiambartolomei@centura.org  

Principal Investigator: John Campana, MD

 

For further information regarding the clinical trial please contact Merrill Biel, MD PhD, Chief Medical Officer, at the following email: Merrill_Biel@aspyriantherapeutics.com